{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '14. Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, et al. Pulsed monoclonal antibody', 'treatment and auto- immune thyroid disease in multiple sclerosis. The Lancet. 1999;354:1691-', '5.', '15. Ghezzi A, Pozzilli C, Grimaldi LME, Moiola L, Brescia-Morra V, Lugaresi A, et al.', 'Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler.', '2013;19,1106-12.', '16. Knechtle SJ, Fernandez LA, Pirsch JD, Becker BN, Chin LT, Becker YT, et al. Campath-1H', 'in renal transplantation: The University of Wisconsin experience. Surgery. 2004;136(4):754-', '60.', '17. Verhey L, Signori A, Arnold D, Amit B, Sadovnick A, Marrie R, et al. Clinical and MRI', 'activity as determinants of sample size for pediatric multiple sclerosis trials. Neurology.', '2013;81 (14) 1215-21.', '18. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic', 'Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Ann Neurol.', '2011;69:292-302.', '19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status', 'scale (EDSS). Neurology. 1983;33(11): 1444-52.', '20. Howie SR. Blood sample volumes in child health research: review of safe limits. Bull World', 'Health Organ. 2011;89(1):46-53.', '21. Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after', 'alemtuzumab. N Engl J Med. 2008;359(7):768-9.', '22. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic', 'opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol.', '2006;253(1):98-108.', '23. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child.', '1969;44:235:291-303.', '24. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis', 'Child. 1970;45:13-23.', \"25. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al.. A\", 'randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J', 'Med. 2006;354(9):899-910.', '26. McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as a surrogate outcome', 'measure in multiple sclerosis. Mult Scler. 2002;8(1):40-51.', '27. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in', 'multiple sclerosis. N Engl J Med. 2000;343(20):1430-8.', 'Property of the Sanofi Group - strictly confidential', 'Page 100', 'VV-CLIN-02544065 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '28. Lublin F. Multiple sclerosis trial designs for the 21st century: building on recent lessons. J', 'Neurol. 2005;252 Suppl 5:v46-53.', '29. Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R; Multiple Sclerosis', 'Outcome Assessments Consortium. Validity of the Symbol Digit Modalities Test as a', 'cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):721-', '33.', '30. Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N et al. Validity of the', 'minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int', 'Neuropsychol Soc. 2006;12(4):549-58', '31. Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P et al. Cognition in', 'multiple sclerosis: State of the field and priorities for the future. Neurology. 2018;90(6):278-', '88.', '32. Stevens K. Developing a descriptive system for a new preference-based measure of health-', 'related quality of life for children. Qual Life Res. 2009;18(8):1105-13.', 'Property of the Sanofi Group - strictly confidential', 'Page 101', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}